APA

Peloquin C. A., Velásquez G. E., Lecca L., Calderón R. I., Coit J., Milstein M., Osso E., Jimenez J., Tintaya K., Sanchez Garavito E., Vargas Vasquez D., Mitnick C. D. & Davies G. (20180406). Pharmacokinetic Evidence from the HIRIF Trial To Support Increased Doses of Rifampin for Tuberculosis. : Antimicrobial agents and chemotherapy.

Chicago

Peloquin C A, Velásquez G E, Lecca L, Calderón R I, Coit J, Milstein M, Osso E, Jimenez J, Tintaya K, Sanchez Garavito E, Vargas Vasquez D, Mitnick C D and Davies G. 20180406. Pharmacokinetic Evidence from the HIRIF Trial To Support Increased Doses of Rifampin for Tuberculosis. : Antimicrobial agents and chemotherapy.

Harvard

Peloquin C. A., Velásquez G. E., Lecca L., Calderón R. I., Coit J., Milstein M., Osso E., Jimenez J., Tintaya K., Sanchez Garavito E., Vargas Vasquez D., Mitnick C. D. and Davies G. (20180406). Pharmacokinetic Evidence from the HIRIF Trial To Support Increased Doses of Rifampin for Tuberculosis. : Antimicrobial agents and chemotherapy.

MLA

Peloquin C A, Velásquez G E, Lecca L, Calderón R I, Coit J, Milstein M, Osso E, Jimenez J, Tintaya K, Sanchez Garavito E, Vargas Vasquez D, Mitnick C D and Davies G. Pharmacokinetic Evidence from the HIRIF Trial To Support Increased Doses of Rifampin for Tuberculosis. : Antimicrobial agents and chemotherapy. 20180406.